Shares of Torrent Pharmaceuticals climbed 2.54% to trade at ₹3,180.65 as of 12:16 PM on November 22. The surge comes after the company announced it has received an Establishment Inspection Report (EIR) from the USFDA for its Pithampur manufacturing facility in Madhya Pradesh.
The EIR, issued with a Voluntary Action Indicated (VAI) classification, confirms the successful closure of the inspection conducted between September 16 and September 20, 2024. This development reinforces Torrent Pharma’s compliance with regulatory standards, boosting investor confidence.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
